<DOC>
	<DOCNO>NCT01514500</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) NNC0195-0092 compare placebo healthy male subject .</brief_summary>
	<brief_title>First Human Dose Trial NNC0195-0092 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Healthy , nonsmoking male subject BMI ( body mass index ) 18.0 28.0 kg/m^2 , incl . Body weight 50 100 kg , incl . Strenuous exercise within 4 day prior dose Receipt investigational medicinal product within 3 month prior randomisation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>